Product Code: GVR-4-68038-999-9
Hereditary Testing Market Growth & Trends:
The global hereditary testing market size is expected to reach USD 13.6 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.2% from 2022 to 2030. Key factors driving the market are the declining cost of sequencing and the availability of genetic tests at a lower price. Furthermore, the availability of niche and fragmented point solutions across the genomics value chain, namely sequencing, analytics, interpretation, aggregation, and marketplace, is anticipated to propel the market growth over the forecast period.
The advent of direct-to-consumer genetics is anticipated to play a major role in the genetic testing market by enabling individuals to carry out self-testing. This expands the role of genetic counselors, which further aids in understanding the importance of genetic tests and helps in the selection of appropriate tests. A growing number of registered genetic counselors is anticipated to boost the adoption of hereditary genetic tests in the coming years.
Another important market trend is the growing field of reproductive genetic health. For instance, Natera has seen a consistent increase in test numbers in hereditary illnesses genetic analysis for women's health. This indicates a rise in public acceptance of hereditary testing, which is fueling the market expansion. A rise in the trade of newborn screening equipment has corresponded with a rise in the trade of DNA experiment equipment. Progressing the sharpness of newborn screening all over the world is also assisting in earnings increase. A multigene board trial was formed for introducing genetic melanoma into the clinical application, which has been prompted by changes in genetic experimentation standards. The growing generative hereditary health scope is one of the most important key factors driving the market.
The COVID-19 pandemic had a detrimental impact on the market. For example, after the World Health Organization declared COVID-19 a pandemic, governments all around the world used lockdowns to compel social distancing as a prophylactic measure. In every industry, this resulted in upheaval, constraints, challenges, and adjustments. Similarly, the outbreak has a negative impact on the inherited genetic analysis sector.
Technology developers are introducing advanced products to enhance the efficiency of genetic tests by diagnostic companies. For example, in December 2020, the QuantiFERON SARS-CoV-2 RUO solution was introduced by QIAGEN, a business that provides technologies and products for pre-analytical samples and related molecular test solutions. The solution detects immune system T-cell responses to the infection that causes COVID-19. The solution would give precise information on illness development and immunity levels.
Hereditary Testing Market Report Highlights:
- The hereditary cancer testing disease type segment is expected to expand at a considerable rate over the forecast period. A substantial number of CLIA-certified laboratories perform tests to determine whether an individual carries an inherited mutated gene that can cause cancer
- The breast cancer testing segment dominated the hereditary cancer testing market in 2021 owing to its high penetration and increased inheritability. Most of the cases of cervical cancer are non-hereditary, resulting in the lowest revenue share of this segment
- In the hereditary non-cancer testing disease type segment, the cardiac diseases segment is driven by the emergence of high-throughput sequencing, which has resulted in the commercial availability of a significant number of sequencing assays for cardiomyopathies
- The Non-invasive Prenatal Testing (NIPT) and cancer screening tests segment and the newborn genetic screening segment continue to witness lucrative growth due to the increased adoption across the globe
- Moreover, the newborn screening program has been made mandatory in several regions and countries, resulting in the growth of newborn genetic screening in the hereditary non-cancer testing disease type segment
- Europe and North America collectively accounted for over 65.0% share of the overall revenue in 2021 owing to the assisted reproductive technology space, coupled with the high penetration of newborn genetic screening
- Key companies are engaged in securing regulatory approval in emerging countries to expand their business footprint. A substantial number of diagnostic companies have collaborated with technology developers to obtain technology licenses and deliver high-value services to their customers
Table of Contents
Chapter 1 Research Methodology
- 1.1 Information Procurement
- 1.2 Information or Data Analysis
- 1.3 Market Formulation & Validation
- 1.4 Market Scope & Segment Definition
- 1.4.1 Hereditary cancer testing
- 1.4.2 Hereditary non-cancer testing
- 1.4.2.1 Genetic tests
- 1.4.2.2 Newborn genetic screening
- 1.4.2.3 Preimplantation genetic diagnosis & screening
- 1.4.2.4 Non-invasive Prenatal Testing (NIPT) & carrier screening tests
- 1.5 Market Model
- 1.5.1 Hereditary cancer testing market
- 1.5.1.1 Market study
- 1.5.1.1.1 Price case study
- 1.5.1.1.2 Test provision study
- 1.5.1.1.3 Market competition study
- 1.5.1.1.4 Reimbursement study
- 1.5.1.2 Product mapping by cancer type & company
- 1.5.2 Hereditary non-cancer genetic testing market
- 1.5.2.1 Newborn genetic screening market
- 1.5.2.2 Preimplantation genetic testing market; NIPT & carrier screening market
Chapter 2 Executive Summary
- 2.1 Market Snapshot (2021, USD Millions)
Chapter 3 Hereditary Testing Market Variables, Trends, & Scope
- 3.1 Market Segmentation & Scope
- 3.2 Market Dynamics
- 3.2.1 Market driver analysis
- 3.2.1.1 Increase in sales and demand for DNA test kits
- 3.2.1.2 Constantly developing commercial landscape of women's reproductive health
- 3.2.1.3 Decline in sequencing cost & consequent expansion of genetic testing registry
- 3.2.2 Market restraints analysis
- 3.2.2.1 Ethical and clinical issues of DNA tests
- 3.2.2.2 Regulatory challenges pertaining to use of DTC genetic tests
- 3.2.3 Market opportunity analysis
- 3.2.3.1 Increasing incidence of genetic diseases
- 3.2.3.2 Presence of demand for early and non-invasive fetal testing procedures
- 3.2.3.3 Introduction of fragmented point-solutions across the genomics value chain
- 3.3 Industry Pyramid Analysis
- 3.4 Technology Mapping
- 3.4.1 PGS Technology Analysis
- 3.4.1.1 aCGH
- 3.4.1.2 NGS
- 3.4.1.3 Others
- 3.4.1.4 Introduction of technological advancements in cloud computing and data integration
- 3.5 Regulatory Landscape, by Geography
- 3.5.1 U.S.
- 3.5.2 Europe
- 3.5.3 China
- 3.5.4 Japan
- 3.6 Penetration & Growth Prospect Mapping, Disease Type, 2021
- 3.7 Hereditary Testing Market-SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
- 3.8 Industry Analysis - Porter's Five Forces
Chapter 4 Hereditary Testing Market: Disease Type Estimates & Trend Analysis
- 4.1 Hereditary Testing Market: Disease Type Movement Analysis
- 4.2 Hereditary Cancer Testing
- 4.2.1 Global hereditary cancer testing market, 2018 - 2030 (USD Million)
- 4.2.2 Lung cancer
- 4.2.2.1 Global hereditary cancer testing market for lung cancer, 2018 - 2030 (USD Million)
- 4.2.3 Breast cancer
- 4.2.3.1 Global hereditary cancer testing market for breast cancer, 2018 - 2030 (USD Million)
- 4.2.4 Colorectal cancer
- 4.2.4.1 Global hereditary cancer testing market for colorectal cancer, 2018 - 2030 (USD Million)
- 4.2.5 Cervical cancer
- 4.2.5.1 Global hereditary cancer testing market for cervical cancer, 2018 - 2030 (USD Million)
- 4.2.6 Ovarian cancer
- 4.2.6.1 Global hereditary cancer testing market for ovarian cancer, 2018 - 2030 (USD Million)
- 4.2.7 Prostate cancer
- 4.2.7.1 Global hereditary cancer testing market for prostate cancer, 2018 - 2030 (USD Million)
- 4.2.8 Stomach/gastric cancer
- 4.2.8.1 Global hereditary cancer testing market for stomach/gastric cancer, 2018 - 2030 (USD Million)
- 4.2.9 Melanoma
- 4.2.9.1 Global hereditary cancer testing market for melanoma, 2018 - 2030 (USD Million)
- 4.2.10 Sarcoma
- 4.2.10.1 Global hereditary cancer testing market for sarcoma, 2018 - 2030 (USD Million)
- 4.2.11 Uterine cancer
- 4.2.11.1 Global hereditary cancer testing market for uterine cancer, 2018 - 2030 (USD Million)
- 4.2.12 Pancreatic cancer
- 4.2.12.1 Global hereditary cancer testing market for pancreatic cancer, 2018 - 2030 (USD Million)
- 4.2.13 Other cancers
- 4.2.13.1 Global hereditary cancer testing market for other cancers, 2018 - 2030 (USD Million)
- 4.3 Hereditary Non-cancer Testing
- 4.3.1 Global hereditary non-cancer testing market, 2018 - 2030 (USD Million)
- 4.3.2 Hereditary non-cancer genetic testing
- 4.3.2.1 Global hereditary non-cancer genetic testing market, 2018 - 2030 (USD Million)
- 4.3.2.2 Hereditary genetic testing for cardiac disease
- 4.3.2.2.1 Global hereditary genetic testing market for cardiac diseases, 2018 - 2030 (USD Million)
- 4.3.2.3 Hereditary genetic testing for rare disease
- 4.3.2.3.1 Global hereditary genetic testing market for rare diseases, 2018 - 2030 (USD Million)
- 4.3.2.4 Hereditary genetic testing for other diseases
- 4.3.2.4.1 Global hereditary genetic testing market for other diseases, 2018 - 2030 (USD Million)
- 4.3.3 Newborn genetic screening
- 4.3.3.1 Global newborn genetic screening market for inherited conditions, 2018 - 2030 (USD Million)
- 4.3.4 Preimplantation Genetic Diagnosis & Screening (PGD/PGS)
- 4.3.4.1 Global PGD/PGS market for inherited conditions, 2018 - 2030 (USD Million)
- 4.3.5 Non-invasive prenatal testing (NIPT) & carrier screening
- 4.3.5.1 Global non-invasive prenatal testing (NIPT) & carrier screening tests market for inherited conditions, 2018 - 2030 (USD Million)
Chapter 5 Hereditary Testing Market Categorization: Regional Estimates & Trend Analysis by Disease Type
- 5.1 Hereditary Testing Market Share By Region
- 5.2 North America
- 5.2.1 North America hereditary testing market, 2018 - 2030 (USD Million)
- 5.2.2 U.S.
- 5.2.2.1 U.S. hereditary testing market, by disease type, 2018 - 2030 (USD Million)
- 5.2.3 Canada
- 5.2.3.1 Canada hereditary testing market, by disease type, 2018 - 2030 (USD Million)
- 5.3 Europe
- 5.3.1 Europe hereditary testing market, by disease type, 2018 - 2030 (USD Million)
- 5.3.2 U.K.
- 5.3.2.1 U.K. hereditary testing market, by disease type, 2018 - 2030 (USD Million)
- 5.3.3 Germany
- 5.3.3.1 Germany hereditary testing market, by disease type, 2018 - 2030 (USD Million)
- 5.3.4 France
- 5.3.4.1 France hereditary testing market, by disease type, 2018 - 2030 (USD Million)
- 5.3.5 Spain
- 5.3.5.1 Spain hereditary testing market, by disease type, 2018 - 2030 (USD Million)
- 5.3.6 Italy
- 5.3.6.1 Italy hereditary testing market, by disease type, 2018 - 2030
- 5.3.7 Netherlands
- 5.3.7.1 Netherlands hereditary testing market, by disease type, 2018 - 2030 (USD Million)
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific hereditary testing market, by disease type, 2018 - 2030 (USD Million)
- 5.4.2 China
- 5.4.2.1 China hereditary testing market, by disease type, 2018 - 2030 (USD Million)
- 5.4.3 Japan
- 5.4.3.1 Japan hereditary testing market, by disease type, 2018 - 2030 (USD Million)
- 5.4.4 India
- 5.4.4.1 India hereditary testing market, by disease type, 2018 - 2030 (USD Million)
- 5.4.5 South Korea
- 5.4.5.1 South Korea hereditary testing market, by disease type, 2018 - 2030 (USD Million)
- 5.4.6 Australia
- 5.4.6.1 Australia hereditary testing market, by disease type, 2018 - 2030 (USD Million)
- 5.4.7 Singapore
- 5.4.7.1 Singapore hereditary testing market, by disease type, 2018
- 5.4.8 South East Asia
- 5.4.8.1 South East Asia hereditary testing market, by disease type, 2018 - 2030 (USD Million)
- 5.5 Latin America
- 5.5.1 Latin America hereditary testing market, by disease type, 2018 - 2030 (USD Million)
- 5.5.2 Brazil
- 5.5.2.1 Brazil hereditary testing market, by disease type, 2018 - 2030 (USD Million)
- 5.6 Middle East and Africa (MEA)
- 5.6.1 MEA hereditary testing market, by disease type, 2018 - 2030 (USD Million)
- 5.6.2 South Africa
- 5.6.2.1 South Africa hereditary testing market, by disease type, 2018 - 2030 (USD Million)
Chapter 6 Competitive Landscape
- 6.1 Major Deals & Strategic Alliances Analysis
- 6.1.1 Merger & acquisition deals
- 6.1.2 Product launches
- 6.1.3 Technological & marketing collaboration
- 6.2 Company Profiles
- 6.2.1 Myriad Genetics, Inc.
- 6.2.1.1 Company overview
- 6.2.1.2 Counsyl, Inc.
- 6.2.1.2.1 Company overview
- 6.2.1.3 Financial performance
- 6.2.1.4 Product benchmarking
- 6.2.1.5 Strategic initiatives
- 6.2.2 Invitae Corporation
- 6.2.2.1 Company overview
- 6.2.2.2 Financial performance
- 6.2.2.3 Product benchmarking
- 6.2.2.4 Strategic initiatives
- 6.2.3 Illumina, Inc.
- 6.2.3.1 Company overview
- 6.2.3.2 Financial performance
- 6.2.3.3 Product benchmarking
- 6.2.3.4 Strategic initiatives
- 6.2.4 Natera Inc.
- 6.2.4.1 Company overview
- 6.2.4.2 Financial performance (Novartis AG)
- 6.2.4.3 Product benchmarking
- 6.2.4.4 Strategic initiatives
- 6.2.5 Laboratory Corporation of America Holdings
- 6.2.5.1 Company overview
- 6.2.5.1.1 Sequenom
- 6.2.5.2 Financial performance
- 6.2.5.3 Financial performance
- 6.2.5.4 Product benchmarking
- 6.2.5.5 Strategic initiatives
- 6.2.6 F. Hoffmann-La Roche Ltd.
- 6.2.6.1 Company overview
- 6.2.6.2 Ariosa Diagnostics
- 6.2.6.3 Financial performance
- 6.2.6.4 Product benchmarking
- 6.2.6.5 Strategic initiatives
- 6.2.7 Quest Diagnostics Incorporated
- 6.2.7.1 Company overview
- 6.2.7.2 Financial Performance
- 6.2.7.3 Product Benchmarking
- 6.2.7.4 Strategic initiatives
- 6.2.8 CooperSurgical, Inc.
- 6.2.8.1 Company overview
- 6.2.8.1.1 Genesis Genetics
- 6.2.8.1.2 Reprogenetics
- 6.2.8.2 Financial performance
- 6.2.8.3 Financial performance
- 6.2.8.4 Product benchmarking
- 6.2.8.5 Strategic initiatives
- 6.2.9 Agilent Technologies, Inc.
- 6.2.9.1 Company overview
- 6.2.9.2 Financial performance
- 6.2.9.3 Product benchmarking
- 6.2.9.4 Strategic initiatives
- 6.2.10 Thermo Fisher Scientific, Inc.
- 6.2.10.1 Company overview
- 6.2.10.1.1 Life Technologies Corp.
- 6.2.10.2 Financial performance
- 6.2.10.3 Product benchmarking
- 6.2.10.4 Strategic initiatives
- 6.2.11 Twist Bioscience
- 6.2.11.1 Company overview
- 6.2.11.2 Financial performance
- 6.2.11.3 Product benchmarking
- 6.2.11.4 Strategic initiatives
- 6.2.12 Sophia Genetics
- 6.2.12.1 Company overview
- 6.2.12.2 Financial performance
- 6.2.12.3 Product benchmarking
- 6.2.12.4 Strategic initiatives
- 6.2.13 Fulgent Genetics, Inc.
- 6.2.13.1 Company overview
- 6.2.13.2 Financial performance
- 6.2.13.3 Product benchmarking
- 6.2.13.4 Strategic initiatives
- 6.2.14 MedGenome
- 6.2.14.1 Company overview
- 6.2.14.2 Financial performance
- 6.2.14.3 Product benchmarking
- 6.2.15 CENTOGENE N.V.
- 6.2.15.1 Company overview
- 6.2.15.2 Financial performance
- 6.2.15.3 Product benchmarking
- 6.2.15.4 Strategic initiatives